Who are Allergovac Poliplus's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ALK HDM AIT 6 DU, ALK HDM AIT 12 DU.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/allergovac-poliplus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Allergovac Poliplus — Competitive Intelligence Brief

Allergovac Poliplus (Allergovac Poliplus) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allergen immunotherapy vaccine. Area: Immunology / Allergy.

phase 2 Allergen immunotherapy vaccine Immunology / Allergy Biologic Live · refreshed every 30 min

Target snapshot

Allergovac Poliplus (Allergovac Poliplus) — Roxall Medicina España S.A. Allergovac Poliplus is an allergen immunotherapy vaccine designed to desensitize the immune system to multiple allergens through controlled exposure.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Allergovac Poliplus TARGET	Allergovac Poliplus	Roxall Medicina España S.A	phase 2	Allergen immunotherapy vaccine
ALK HDM AIT 6 DU	ALK HDM AIT 6 DU	ALK-Abelló A/S	phase 3	Allergen immunotherapy vaccine	House dust mite allergens (Der p 1, Der p 2, Der f 1, Der f 2)
ALK HDM AIT 12 DU	ALK HDM AIT 12 DU	ALK-Abelló A/S	phase 3	Allergen immunotherapy vaccine	House dust mite allergens (Der p 1, Der p 2, and other HDM proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allergen immunotherapy vaccine class)

ALK-Abelló A/S · 2 drugs in this class
Roxall Medicina España S.A · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Allergovac Poliplus — Competitive Intelligence Brief. https://druglandscape.com/ci/allergovac-poliplus. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab